Joseph Osarfo1, Rose O Adjei2, Pascal Magnussen3, Harry K Tagbor1. 1. Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. 2. Department of Health Education, School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. 3. Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: With increasing orientation towards including pregnant women in clinical trials, investigators must conduct culturally acceptable research to aid recruitment and retention. There is limited information on experiences and meanings that pregnant women make of trial participation in Africa. This study reports experiences and perceptions of Ghanaian pregnant women regarding their participation in a clinical trial. METHODS: From October to December 2012, 45 in-depth interviews were conducted among pregnant women and their male partners regarding their experiences and perceptions of clinical trial processes as part of an antimalarial drug safety and efficacy trial in pregnant women in the Ashanti region of Ghana. Analysis was by predetermined themes and inductive analysis. RESULTS: Familiarity with the disease studied in the trial and trust in health workers favoured participation with the latter underlying acceptance of study drugs in the absence of symptoms. Adverse drug events were perceived as intrinsic sickness exhibited on the path to wellness. There were no cultural barriers to blood sampling during home visits but hospital-based sampling was preferred. Home visits were linked to participants having HIV infection. CONCLUSION: This study contributes knowledge on sociocultural matters underpinning pregnant women's decisions regarding trial participation in an era of increasing drug trials involving pregnant women.
BACKGROUND: With increasing orientation towards including pregnant women in clinical trials, investigators must conduct culturally acceptable research to aid recruitment and retention. There is limited information on experiences and meanings that pregnant women make of trial participation in Africa. This study reports experiences and perceptions of Ghanaian pregnant women regarding their participation in a clinical trial. METHODS: From October to December 2012, 45 in-depth interviews were conducted among pregnant women and their male partners regarding their experiences and perceptions of clinical trial processes as part of an antimalarial drug safety and efficacy trial in pregnant women in the Ashanti region of Ghana. Analysis was by predetermined themes and inductive analysis. RESULTS: Familiarity with the disease studied in the trial and trust in health workers favoured participation with the latter underlying acceptance of study drugs in the absence of symptoms. Adverse drug events were perceived as intrinsic sickness exhibited on the path to wellness. There were no cultural barriers to blood sampling during home visits but hospital-based sampling was preferred. Home visits were linked to participants having HIV infection. CONCLUSION: This study contributes knowledge on sociocultural matters underpinning pregnant women's decisions regarding trial participation in an era of increasing drug trials involving pregnant women.
Authors: Owusu Boahen; Seth Owusu-Agyei; Lawrence Gyabaa Febir; Charlotte Tawiah; Theresa Tawiah; Samuel Afari; Samuel Newton Journal: Trans R Soc Trop Med Hyg Date: 2013-02-20 Impact factor: 2.184
Authors: Joseph Mfutso-Bengo; Paul Ndebele; Vincent Jumbe; Matilda Mkunthi; Francis Masiye; Sassy Molyneux; Malcolm Molyneux Journal: Malawi Med J Date: 2008-06 Impact factor: 0.875
Authors: Lawrence G Febir; Kwaku P Asante; Dan-Bright S Dzorgbo; Kojo A Senah; Timothy S Letsa; Seth Owusu-Agyei Journal: Malar J Date: 2013-05-07 Impact factor: 2.979
Authors: Lucy A Smith; Caroline Jones; Rose O Adjei; Gifty D Antwi; Nana A Afrah; Brian Greenwood; Daniel Chandramohan; Harry Tagbor; Jayne Webster Journal: Malar J Date: 2010-01-14 Impact factor: 2.979